PMID: 9167843May 1, 1997Paper

Decreased whole blood factor IX activity following hemodilution with hemoglobin A-zero in-vitro

Artificial Cells, Blood Substitutes, and Immobilization Biotechnology
M S KimA G Greenburg

Abstract

Previous studies of hemoglobin-based oxygen carriers and their effects on coagulation have shown conflicting results. This study re-examined the effect of hemoglobin solution on blood coagulation in whole blood using highly purified human hemoglobin Ao (HbAo). Citrated human whole blood samples were diluted 1:1 with HbAo (7gHb/dl) or human serum albumin (HSA; 5g/dl) as a protein control, and both activated partial thromboplastin time (aPTT) and prothrombin time (PT) were measured using a mechanically based whole blood coagulometer. Multiple runs were performed with the same volunteer donor sample. The mean aPTT time of HbAo-diluted samples (105.9 +/- 19.9 sec., n = 41) was significantly longer than the undiluted controls (46.4 +/- 5.6 sec., n = 54) or HSA-diluted blood (77.1 +/- 12.7 sec., n = 41) indicating an abnormal intrinsic coagulation pathway. There was no significant difference between the PT times of the HbAo and HSA-diluted samples. To examine the cause of the prolonged aPTT times with HbAo dilution, we performed activity assays of intrinsic factors XII, XI, IX, and VIII in a citrated human whole blood system diluted 1/5 and 1/10 with normal saline solution (NSS), and then 1:1 with either HbAo, HSA, or NSS. Only the F...Continue Reading

References

Jan 1, 1978·Clinical Pharmacology and Therapeutics·J P SavitskyJ D Arnold
Mar 13, 1990·Biochemistry·R Rawala-SheikhP N Walsh
Sep 25, 1981·Molecular and Cellular Biochemistry·J P BurnierB Furie
Jan 1, 1994·Artificial Cells, Blood Substitutes, and Immobilization Biotechnology·H W KimA G Greenburg

❮ Previous
Next ❯

Citations

Feb 26, 1999·Annals of Emergency Medicine·E M Ketcham, C B Cairns

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

Artificial Cells, Blood Substitutes, and Immobilization Biotechnology
L C CernyE R Cerny
The Journal of Laboratory and Clinical Medicine
R M Winslow
Artificial Cells, Blood Substitutes, and Immobilization Biotechnology
A Usuba, R Motoki
© 2021 Meta ULC. All rights reserved